Dimitra Ioanna Lampropoulou1, Vanessa Meletia Bala2, Eleni Zerva2, Evangelia Pliakou2, Dimitrios Filippou3, Maria Gazouli4, Gerasimos Aravantinos2. 1. Second Department of Medical Oncology, General Oncology Hospital of Kifissia "Agioi Anargiroi", Athens, Nea Kifissia, Greece. d_lambropoulou@yahoo.gr. 2. Second Department of Medical Oncology, General Oncology Hospital of Kifissia "Agioi Anargiroi", Athens, Nea Kifissia, Greece. 3. Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 4. Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
INTRODUCTION: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments. METHODOLOGY: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection. RESULTS: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients. CONCLUSIONS: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis. Copyright (c) 2022 Dimitra Ioanna Lampropoulou, Vanessa Meletia Bala, Eleni Zerva, Evangelia Pliakou, Dimitrios Filippou, Maria Gazouli, Gerasimos Aravantinos.
INTRODUCTION: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments. METHODOLOGY: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection. RESULTS: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients. CONCLUSIONS: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis. Copyright (c) 2022 Dimitra Ioanna Lampropoulou, Vanessa Meletia Bala, Eleni Zerva, Evangelia Pliakou, Dimitrios Filippou, Maria Gazouli, Gerasimos Aravantinos.